Role of endothelin in fibrosis and anti‐fibrotic potential of bosentan

References

• Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol. 1994;21:1268–76.
   PubMed Web of Science ®Google Scholar
• Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol. 1992; 19:1566–71.
   PubMed Web of Science ®Google Scholar
• Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130–4.
   Google Scholar
• Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Chin Invest. 1997;99:1380–9.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Fouassier L, Chung jj, Carayon A, Vallee P, Rey C, et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology. 1998;27:472–80.
   PubMed Web of Science ®Google Scholar
• Kahaleh MB. Endothelin, an endothelial-dependent vaso-constrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 1991;34:978–83.
   PubMed Web of Science ®Google Scholar
• Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res. 1995;287:439–42.
   PubMed Web of Science ®Google Scholar
• Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol. 1994;21: 1838–44.
   Google Scholar
• Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois R14, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol. 1994;11: 439–45.
   Google Scholar
• Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997;151:831–41.
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, Kusserow H, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol. 2000;23: 19–26.
   Google Scholar
• Zhang Y, Geng H, Zhao M, Zou W, E J, Zheng X, et al. The significance of anti-endothelial cell antibodies in patients with lupus nephritis and immunoblotting analysis of the target components. Chin Med J. 1999;112:597–602.
   PubMed Web of Science ®Google Scholar
• Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol. 2000;119:203–9.
   PubMed Web of Science ®Google Scholar
• Yurdak-ul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol. 2004;16:38–42.
   PubMedGoogle Scholar
• Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25:462–6.
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Chin Invest. 1996;98:785–92.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Geshi Y, Kuno S, Kase N, Mori H. Anti-endothelial cell antibody in preeclampsia: clinical findings and serum cytotoxicity to endothelial cell. Nihon Rinsho Meneki Gakkai Kaishi. 1998;21:191–7.
   Google Scholar
• Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550–62.
   PubMed Web of Science ®Google Scholar
• Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation. 1995;92:2969–74.
   PubMed Web of Science ®Google Scholar
• Clozel M, Breu V, Gray GA, Kalina B, Loftier BM, Burn K, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antago-nist. J Pharmacol Exp Ther. 1994;270:228–35.
   PubMed Web of Science ®Google Scholar
• Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:2125–9.
   Google Scholar
• Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem. 1989;264: 7856–61.
   Google Scholar
• Shi-wen X, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix bio-synthesis and proliferation in normal and scleroderma fibro-blasts. J Cardiovasc Pharmacol. 1998;31 (Suppl 1):5360–3.
   Google Scholar
• Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts prolif-eration in interstitial lung diseases. Int J Immunopharmacol. 1999;21:759–75.
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ. Endothelin-1 and endothelin-3 induce chemo-taxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 1992;7:492–9.
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Katwa L, Spadone DP, Myers PR. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol. 1996;28:243–52.
   PubMed Web of Science ®Google Scholar
• Marini M, Carpi S, Bellini A, Patalano F, Mattoli S. Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun. 1996;220: 896–9.
   Google Scholar
• Shi-wen X, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ ERK. J Biol Chem. 2004;279: 23098–103.
   Google Scholar
• Shi-wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol. 2001;116: 417–25.
   Google Scholar
• Flamant M, Tharaux PL, Placier S, Hem-ion D, Coffman T, Chatziantoniou C, et al. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J. 17327–9.
   Google Scholar
• Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J. 2003;22:69–76.
   PubMed Web of Science ®Google Scholar
• Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity. 1999;31:195–214.
   PubMed Web of Science ®Google Scholar
• Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol. 2002;29:2558–64.
   PubMed Web of Science ®Google Scholar
• Gonzalez W, Chen Z, Damon DH. Transforming growth factor-beta regulation of endothelin expression in rat vascular cell and organ cultures. J Cardiovasc Pharmacol. 2001;37:219–26.
   Google Scholar
• Zoja C, Orisio S, Perico N, Benigni A, Morigi M, Benatti L, et al. Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Lab Invest. 1991;64:16–20.
   PubMed Web of Science ®Google Scholar
• Harada M, Itoh H, Nakagawa 0, Ogawa Y, Miyamoto Y, Kuwahara K, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 1997;96: 3737–44.
   Google Scholar
• Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res. 2003;92:1288–95.
   PubMed Web of Science ®Google Scholar
• Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int. 2000;58:2367–76.
   PubMed Web of Science ®Google Scholar
• Yeh YC, Burns ER, Yeh J, Yeh HW. Synergistic effects of endothelin-1 (ET-1) and transforming growth factor alpha (TGF-alpha) or epidermal growth factor (EGF) on DNAreplication and G1 to S phase transition. Biosci Rep. 1991;11:171–80 .
   PubMed Web of Science ®Google Scholar
• Dube J, Chakir J, Dube C, Grimard Y, Laviolette M, Boulet LP. Synergistic action of endothelin (ET)-1 on the activation of bronchial fibroblast isolated from normal and asthmatic subjects. hit J Exp Pathol. 2000;81:429–37.
   PubMed Web of Science ®Google Scholar
• Chen J, Gu Y, Lin F, Yang H, Zhu W, Ma J, et al. Endo-thelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chin Med J. 2002;115:972–8.
   PubMed Web of Science ®Google Scholar
• Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Born A, Bellini G. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol. 2003;42:752–6.
   PubMed Web of Science ®Google Scholar
• Schafhalter-Zoppoth I, Gray MO, Teerlink JR. Endothelin antagonism with bosentan, a dual receptor blocker, nor-malizes dysregulated transforming growth factor beta signal-ing pathways in rats with chronic heart failure. J Am Coll Cardiol. 2002;39:171A.
   Google Scholar
• Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morpho-genetic protein receptor-II gene. Am J Hum Genet. 2000;67:737–44.
   PubMed Web of Science ®Google Scholar
• Thomson J, Machado R, Pauciulo M, Morgan N, Yacoub M, Corns P, et al. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene muta-tions resulting in haploinsufficiency of the bone morpho-genetic protein type II receptor. J Heart Lung Transplant. 2001;20:149.
   PubMedGoogle Scholar
• Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105:1672–8.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001;104:790–5.
   PubMed Web of Science ®Google Scholar
• Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, et al. Functional analysis of bone morphogenetic protein type II receptor mutations under-lying primary pulmonary hypertension. Hum Mol Genet. 2002;11:1517–25.
   PubMed Web of Science ®Google Scholar
• Kawamura H, Otsuka T, Matsuno H, Niwa M, Matsui N, Kato K, et al. Endothelin-1 stimulates heat shock protein 27 induction in osteoblasts: involvement of p38 MAP kinase. Am J Physiol. 1999;277(6 Pt 1):E1046–54.
   Google Scholar
• Kozawa O, Kawamura H, Hatakeyama D, Matsuno H, Uematsu T. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase. Cell Signal. 2000;12: 375–80.
   Google Scholar
• Pikkarainen S, Tokola H, Kerkela R, Majalahti-Palviainen T, Vuolteenaho 0, Ruskoaho H. Endothelin-1-specific activa-tion of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors. J Biol Chem. 2003;278: 3969–75.
   Google Scholar
• Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 2000;36:282–90.
   PubMed Web of Science ®Google Scholar
• Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria:role of angiotensin II and endothelin-1. Hypertension. 2001;37: 1171–8.
   Google Scholar
• Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 2003;284:E1089–97.
   Web of Science ®Google Scholar
• Wilson SH, Simari RD, Lerman A. The effect of endothelin-1 on nuclear factor kappa B in macrophages. Biochem Biophys Res Commun. 2001;286: 968–72.
   Google Scholar
• Finsnes F, Lyberg T, Christensen G, Skjonsberg OH. Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2001;280:L659–65.
   PubMed Web of Science ®Google Scholar
• Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med. 2003;35:605–13.
   Google Scholar
• McLaughlin V, Sitbon 0, Rubin LJ, Levy P, Barst R, Badesch D, et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 2003;167:A441.
   Google Scholar
• Nguyen QT, Cernacek P, Calderoni A, Stewart DJ, Picard P, Sirois P, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation. 1998;98:2323–30.
   PubMed Web of Science ®Google Scholar
• Hu K, Gaudron P, Schmidt TJ, Hoffmann KD, Ertl G. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. J Cardiovasc Pharmacol. 1998;32: 505–8.
   Google Scholar
• Hocher B, George I, Diekmann F, Zart R, Rebstock J, Schwarz A, et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens. 2000;18:1807–14.
   PubMed Web of Science ®Google Scholar
• Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension. 1999;33:816–22.
   PubMed Web of Science ®Google Scholar
• Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, et al. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation. 2000;102:491–3.
   PubMed Web of Science ®Google Scholar
• Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol. 2000;32: 1621–9.
   Google Scholar
• Chen S, Evans T, Deng D, Cukiernik M, Chakrabarti S. Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron. 2002;90:86–94.
   Google Scholar
• Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49:662–6.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinosi-tide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15: 2707–19.
   Google Scholar
• Mansoor AM, Honda M, Saida K, Ishinaga Y, Kuramochi T, Maeda A, et al. Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun. 1995;215:981–6.
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs ofpatients with pulmonary hypertension. N Engl J Med. 1993;328:1732–9.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185–97.
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Grit Care Med. 1997;156(2 Pt 1):600–8.
   Google Scholar
• Mutsaers SE, Foster ML, Chambers RC, Laurent GJ, McAnulty RJ. Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am J Respir Cell Mol Biol. 1998;18: 611–9.
   Google Scholar
• Mutsaers SE, Marshall RP, Goldsack NR, Laurent GJ, McAnulty RJ. Effect of endothelin receptor antagonists (BQ-485, Ro 47–0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 1998;11: 221–5.
   Google Scholar
• Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993;341: 1550–4.
   PubMed Web of Science ®Google Scholar
• Takeda S, Sawa Y, Minami M, Kaneda Y, Fujii Y, Shirakura R, et al. Experimental bronchiolitis obliterans induced by in vivo HVJ-liposome-mediated endothelin-1 gene transfer. Ann Thorac Surg. 1997;63:1562–7.
   PubMed Web of Science ®Google Scholar
• Merlin SL, Brock GB, Begin LR, Hiou Tim FF, Macramalla AN, Seyam RM, et al. New insights into the role of endothelin-1 in radiation-associated impotence. Int J Impot Res. 2001;13: 104–9.
   Google Scholar
• Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol. 1997;1:47–56.
   PubMedGoogle Scholar
• Burns KE, Piliotis E, Garcia BM, Ferguson KA. Amiodarone pulmonary, neuromuscular and ophthalmolo-gical toxicity. Can Respir J. 2000;7:193–7.
   PubMedGoogle Scholar
• Montanes P, Lawless C, Black C, Oakley CM, Hughes G. The heart in scleroderma: noninvasive assessment. Chin Cardiol. 1982;5:383–7.
   Google Scholar
• Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist. Circulation. 1999;100: 1823–9.
   Google Scholar
• Rossi MA. Fibrosis and inflammatory cells in human chronic chagasic myocarditis: scanning electron microscopy and immunohistochemical observations. hit J Cardiol. 1998;66:183–94.
   Web of Science ®Google Scholar
• Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer. 1995;62: 542–7.
   Google Scholar
• Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001;89: 140–4.
   Google Scholar
• Katwa LC. Cardiac myofibroblasts isolated from the site myocardial infarction express endothelin de novo. Am J Physiol Heart Circ Physiol. 2003;8:8.
   Google Scholar
• Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M, Karliner JS. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol. 2000;32:565–76.
   PubMed Web of Science ®Google Scholar
• Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell. 1994;79:1277–85.
   PubMed Web of Science ®Google Scholar
• Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, et al. Role of endogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976–82.
   PubMed Web of Science ®Google Scholar
• Karam H, Heudes D, Hess P, Gonzales MF, Loffier BM, Clozel M, et al. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res. 1996;31:287–95.
   PubMed Web of Science ®Google Scholar
• Karam H, Heudes D, Bruneval P, Gonzales ME, Loffler BM, Clozel M, et al. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension. 1996;28:379–85.
   Google Scholar
• Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, et al. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol. 2003;41:666–73.
   PubMed Web of Science ®Google Scholar
• Hileeto D, Cukiernik M, Mukherjee S, Evans T, Barbin Y, Downey D, et al. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev. 2002;18:386–94.
   PubMed Web of Science ®Google Scholar
• Rolinski B, Heigermoser A, Lederer E, Bogner JR, Loch 0, Goebel FD. Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy. Infection. 1999;27: 244–7.
   Google Scholar
• Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol. 1993;150:4601–9.
   PubMed Web of Science ®Google Scholar
• Hansen BF. Pathology of the heart in AIDS. A study of 60 consecutive autopsies. APMIS. 1992;100:273–9.
   Google Scholar
• Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1990;1:649–59.
   Google Scholar
• Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19(6 Pt 2):753–7.
   Google Scholar
• Maki S, Miyauchi T, Sakai S, Kobayashi T, Maeda S, Takata Y, et al. Endothelin-1 expression in hearts of transgenic hypertensive mice overexpressing angiotensin II. J Cardiovasc Pharmacol. 1998;31 (Suppl 1):5412–6.
   Google Scholar
• d'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension. 1998;31:1305–10.
   PubMed Web of Science ®Google Scholar
• Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153–9.
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Sawa H, Yasuda H. Effect of endothelin on angiotensin converting enzyme activity in cultured pulmon-ary artery endothelial cells. J Hypertens. 1991;9:171–4.
   Google Scholar
• Ramires FJA, Sun Y, Mady C, Ramires JAF, Weber KT. Effect of endothelin on myocardial fibrosis in response to chronic administration of angiotensin II or aldosterone. Circulation. 1999;100:52500.
   Google Scholar
• Sutsch G, Bertel 0, Rickenbacher P, Clozel M, Yandle TG, Nicholls MG, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol. 2000;85:973–6.
   Google Scholar
• Haggitt RC, Pitcock JA, Muirhead EE. Renal medullary fibrosis in hypertension. Hum Pathol. 1971;2:587–97.
   Google Scholar
• Li JS, Schurch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens. 1996;9:803–11.
   Google Scholar
• Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593–7.
   Google Scholar
• Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation. 1999;99:2185–91.
   PubMed Web of Science ®Google Scholar
• Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int. 1995;47:1546–57.
   PubMed Web of Science ®Google Scholar
• Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int. 1991;40:1020–31.
   PubMed Web of Science ®Google Scholar
• Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromy-cin aminonucleoside nephrosis in rats. Am J Pathol. 1992;141:1381–96.
   PubMed Web of Science ®Google Scholar
• Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290–301.
   PubMed Web of Science ®Google Scholar
• Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Chin Invest. 1998;101:2780–9.
   PubMed Web of Science ®Google Scholar
• Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001;37(2 part 2):490–6.
   Google Scholar
• Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I, et al. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 1996;50:962–72.
   Google Scholar
• Ebihara I, Nakamura T, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metal-loproteinases (MNIP) and a tissue inhibitor of MNIP in aminonucleoside nephrosis. Nephrol Dial Transplant. 1997;12:1001–6.
   PubMed Web of Science ®Google Scholar
• Braun C, Vetter S, Conzelmann T, Schaub M, Kirchengast M, van der Woude FJ, et al. Improved recovery following posttransplant acute renal failure in rat renal isografts with an oral endothelin-A receptor antagonist. Exp Nephrol. 2000;8:283–90.
   Google Scholar
• Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, Lopez-Armada MJ, Plaza JJ, et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expres-sion and synthesis and mesangial cell growth. Hypertension. 1996;27:885–92.
   PubMed Web of Science ®Google Scholar
• Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagentype I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation. 1999;100: 1901–8.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993;328:1828–35.
   Google Scholar
• Gressner AM, Bachem MG. Molecular mechanisms of liver fibrogenesis-a homage to the role of activated fat-storing cells. Digestion. 1995;56:335–46.
   PubMed Web of Science ®Google Scholar
• Gandhi CR, Kuddus RH, Uemura T, Rao AS. Endothelin stimulates transforming growth factor-betal and collagen synthesis in stellate cells from control but not cirrhotic rat liver. Eur J Pharmacol. 2000;406:311–8.
   PubMed Web of Science ®Google Scholar
• Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000;118:1169–78.
   PubMed Web of Science ®Google Scholar
• Rockey DC. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem Biophys Res Commun. 1995;207:725–31.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Chung H. Endothelin antagonism in experi-mental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Chin Invest. 1996;98:1381–8.
   Google Scholar
• Chongsrisawat V, Chatchatee P, Samransamruajkit R, Vanapongtipagom P, Chottivittayatarakorn P, Poovorawan Y. Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension. Pediatr Surg Int. 2003;13:13.
   Google Scholar
• Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol. 2000;95: 199–203.
   Google Scholar
• Yokomori H, Oda M, Ogi M, Kamegaya Y, Tsukada N, Nakamura M, et al. Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver. Liver. 2001;21: 114–22.
   PubMedGoogle Scholar
• Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233–40.
   PubMed Web of Science ®Google Scholar
• Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology. 1998;28:655–9.
   PubMed Web of Science ®Google Scholar
• Cai L, Chen S, Evans T, Deng DX, Mukherjee K, Chakrabarti S. Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism. Urol Res. 2000;28:342–7.
   PubMedGoogle Scholar
• Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (Oxford). 2003;42:191–3.
   PubMed Web of Science ®Google Scholar